A common diabetes drug may protect the heart in a surprising new way. A Vanderbilt University pilot study found that empagliflozin sharply lowers inflammatory cell clumps in the blood. These clumps, called monocyte-platelet aggregates, are known to fuel vascular inflammation and heart disease.

Researchers treated 16 women with obesity and prediabetes for three months. Within just two weeks, the inflammatory clumps dropped clearly. By week 12, the reduction was even stronger. Only the group taking the drug saw the benefit. A comparison group that followed a low-calorie diet did not show the same change.

The team also documented what they call metabolic reprogramming of immune cells. The monocytes shifted from a hyperinflammatory state to a calmer, more stable one focused on normal energy use. Advanced genetic sequencing and cellular imaging backed the findings.

The results were published in the journal Circulation in October 2026. Lead researcher Dr Mona Mashayekhi said this is the first direct proof in humans that this drug class alters immune cells. A larger placebo-controlled trial with 74 participants is now enrolling at Vanderbilt. Doctors caution the study was small, and heart protection is inferred from lower inflammation, not yet proven in hard outcomes.